MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.cgh.2023.06.023

Медицинская библиотека · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023

Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study.

Lemmens Pauline, Louis Edouard, Van Moerkercke Wouter, Pouillon Lieven, Somers Michael, Peeters Harald, Vanden Branden Stijn, Busschaert Julie, Baert Filip, Cremer Anneline, Potvin Philippe, Dewit Sophie, Colard Arnaud, Swinnen Jo, Lambrecht Guy, Claessens Christophe, Willandt Barbara, Dewint Pieter, Van Dyck Evi, Sabino Joao, Vermeire Séverine, Ferrante Marc

Многоцентровое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND & AIMS: Several advanced therapies (biologic therapies and small molecules) have been approved for the treatment of moderate-to-severe ulcerative colitis. The registration trials for these agents typically excluded patients with isolated proctitis, leaving an evidence gap. We evaluated efficacy and safety of advanced therapies in patients with ulcerative proctitis (UP).

METHODS

This multicenter retrospective cohort study included consecutive patients with active UP (Mayo endoscopy subscore of ≥2, rectal inflammation up to 15 cm) initiating advanced therapy, after failing conventional therapy. The primary end point was short-term steroid-free clinical remission (total Mayo score ≤2 with no individual subscore >1). In addition, drug persistence and relapse-free and colectomy-free survival were assessed. Both binary logistic and Cox regression analyses were performed.

RESULTS

In total, 167 consecutive patients (52.0% female; median age 41.0 years; 82.0% bionaive) underwent 223 courses of therapy for UP (38 adalimumab, 14 golimumab, 54 infliximab, 9 ustekinumab, 99 vedolizumab, 9 tofacitinib). The primary end point was achieved with 36.3% of the treatment courses, and based on multivariate analysis, more commonly attained in bionaive patients (P = .001), patients treated with vedolizumab (P = .001), patients with moderate endoscopic disease activity (P = .002), and a body mass index <25 kg/m2 (P = .018). Drug persistence was significantly higher in patients treated with vedolizumab (P < .001) and patients with a shorter disease duration (P = .006). No new safety signals were observed.

CONCLUSIONS

Advanced therapies are also efficacious and safe in patients with ulcerative colitis limited to the rectum. Therefore, the inclusion of patients with UP in future randomized-controlled trials should be considered.

Для цитирования: Lemmens Pauline, Louis Edouard, Van Moerkercke Wouter, Pouillon Lieven, Somers Michael, Peeters Harald, Vanden Branden Stijn, Busschaert Julie, Baert Filip, Cremer Anneline, Potvin Philippe, Dewit Sophie, Colard Arnaud, Swinnen Jo, Lambrecht Guy, Claessens Christophe, Willandt Barbara, Dewint Pieter, Van Dyck Evi, Sabino Joao, Vermeire Séverine, Ferrante Marc. Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study.. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2023. DOI: 10.1016/j.cgh.2023.06.023.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.